Novel dry eye treatment enters UK market

Nordic group BV, the international pharmaceutical company operating as Nordic Pharma, announced that the dry eye treatment, Lacrifill canalicular gel, has received CE mark approval for launch in Europe. 

Lacrifill was described as a cross-linked hyaluronic acid gel that temporarily blocks tear drainage by occluding the canalicular system, preserving the tear film and offering long lasting effects of up to six months. 

Following the launch of Lacrifill in the US last year, the company planned to expand its footprint in Europe, bringing the dry eye treatment to a broader patient population.